Breaking News

Horizon Discovery Licenses ERS Genomics Technology

May 9, 2014

Will use CRISPR/Cas9 gene editing system for research applications

Horizon Discovery has entered into a non-exclusive license agreement with ERS Genomics, Ltd. to access intellectual property for the CRISPR/Cas9 gene editing system. Access to the CRISPR IP portfolio will allow the technology to be deployed extensively across Horizon’s products, services and leveraged R&D.
Horizon gains rights to use the technology for research applications including: development and sale of research tools, kits and reagents, performance of research services, creation of genetically modified disease model cell lines, development and production of reference standard material for molecular diagnostics, and for internal target identification and validation research efforts.
“Horizon Discovery’s ambition is to be the market leader in CRISPR technology, and by expanding our portfolio of intellectual property rights in this area we aim to ensure that our customers, both now and in the future, will have unencumbered access to this innovative new gene editing technology,” said Dr. Darrin Disley, chief executive officer of Horizon Discovery Group. “We believe that the ERS Genomics IP, based on the work of Dr. Emmanuelle Charpentier and her colleagues, is particularly important and so we are very pleased to be able to add it to our expanding portfolio of patent rights in this area on behalf of our customers.”

Related Compliance:

  • Drug Development in Today’s Changing Healthcare Market

    Kristin Brooks, Contract Pharma||January 4, 2017
    John Corcoran of Trinity Partners discusses what’s next for the life sciences industry

  • CROs and Today's R&D Landscape

    Kristin Brooks, Contract Pharma||May 11, 2016
    John Lewis of ACRO discusses opportunities and challenges, global markets, and the future CRO

  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • When Quality Meets Confidence

    When Quality Meets Confidence

    Dr. Fadia AlKhalil, Vice President of Global Business Development for Laboratory Services, SGS ||November 9, 2016
    A look at global account management for R&D outsourcing

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus